EMA approval

MIM PHARMA is predicting SaliraVira® EMA approval during 2021. We are pleased with the progress and the momentum that we’ve been able to make over the past year. Our positive data from Covid-19 patient’s treatments and the clinical trials make us very excited to launch the product in the European market during 2021.